Ignite Creation Date:
2024-05-05 @ 7:08 PM
Last Modification Date:
2024-10-26 @ 9:44 AM
Study NCT ID:
NCT00611962
Status:
COMPLETED
Last Update Posted:
2008-02-11
First Post:
2008-01-28
Brief Title:
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of the oxaliplatin-paclitaxel combination ie evaluation of tumor response rate using World Health OrganizationUnion Internationale Contre le Cancer WHOUICC and Indianapolis tumor marker human chorionic gonadotropin hCG alpha fetoprotein AFP criteria in metastatic germ cell cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None